FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1008-1009 October 12, 1995 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Charache, S. PubMed Citation

To the Editor: Charache et al. (May 18 issue)¹ reported on the efficacy of hydroxyurea in ameliorating some of the complications of sickle cell anemia. In a randomized, double-blind setting, hydroxyurea treatment was associated with a reduced frequency of vaso-occlusive crises, acute chest syndrome, and transfusions, but not of stroke, hepatic sequestration, or death. As the authors emphasized, the encouraging results of this study must be balanced by concern over the carcinogenic or leukemogenic potential of long-term hydroxyurea therapy.

In an accompanying editorial, Schechter and Rodgers² state, "There has been extensive experience with [hydroxyurea's] long-term use — at slightly higher . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Koshy, M., Dorn, L., Bressler, L., Molokie, R., Lavelle, D., Talischy, N., Hoffman, R., van Overveld, W., DeSimone, J. (2000). 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96: 2379-2384 [Abstract] [Full Text]  
• Schechter, A. N., Rodgers, G. P., Adams-Graves, P., Heltsley, C., Deitcher, S. (1996). Hydroxyurea in Sickle Cell Disease. NEJM 334: 333-334 [Full Text]